|MUSINGS, OPINIONS, TIPS AND EXPERIENCES
|Year : 2020 | Volume
| Issue : 2 | Page : 239-242
Washout period for pregnancy post isotretinoin therapy
Hina Jajoria, Venkataram Mysore
Dermatology, Venereology and Leprosy, The Venkat Center for Skin and Plastic Surgery - Post Graduate Training Center (Affiliated to RGUHS), Subbanna Garden, Bengaluru, Karnataka, India
|Date of Web Publication||9-Mar-2020|
The Venkat Center for Skin and Plastic Surgery, Post Graduate Training Center (Affiliated to RGUHS), 3437, 1st ‘G’ Cross, 7th Main, Next to BTS Bus Depot, Subbanna Garden, Bengaluru - 560 040, Karnataka
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Introduction and Background: Isotretinoin is an oral medication used for the treatment of severe acne unresponsive to other medications. This drug is teratogenic and should be prescribed with appropriate caution in selected group of patients. The washout period for pregnancy post isotrenoin therapy has always been a topic of controversy. Several guidelines have recommended a wash out period of one month if pregnancy is planned in a patient being administered with the drug. Objective: This article discusses the available evidence for different recommended wash out periods and addresses important clinical questions that arise. Methods: Pubmed research was carried out to collect relevant data using the keywords isotretinoin, pregnancy, contraception, pharmacokinetics and guidelines. Conclusion: Our research based on the published data concludes that a wash out period of 35 days post isotretinoin therapy is adequate in routine clinical practice.
Keywords: Contraception, India, isotretinoin, new guidelines, pregnancy
|How to cite this article:|
Jajoria H, Mysore V. Washout period for pregnancy post isotretinoin therapy. Indian Dermatol Online J 2020;11:239-42
| Introduction|| |
Isotretinoin is an oral derivative of vitamin A. Oral isotretinoin (13-cis-retinoic acid) was first approved by the US Food and Drug Administration (FDA) for treatment for severe acne in 1982. Isotretinoin is a pro-drug that is converted intracellularly to metabolites that are agonists for Retinoic acid receptor (RAR) and retinoid X receptor (RXR) nuclear receptors.,,, Isotretinoin influences all of the major etiological factors implicated in acne by affecting the cellular differentiation, cell-cycle progression, cell survival, and apoptosis.,,,,,, As a consequence there is a remarkable reduction in sebum production, comedogenesis, surface and ductal Propionibacterium acnes nd inflammation. A dose of 0.5-1.0 mg/kg/day dramatically reduces sebum excretion by 90% within a period of 6 weeks. The average course of treatment is 4-6 months. Isotretinoin is category X drug and one of the most well established and potential serious adverse effect of isotretinoin is teratogenic if not taken under proper guidance. If used in first trimester, it may lead to increased fetal loss and specific malformations like cleft palate, stenosis of the external ear canal, microtia, and hydrocephalus. Cardiac outflow tract defects may occur when consumed later in pregnancy. Therefore, is it contraindicated during pregnancy or in patients who are trying to conceive.
For this reason, strict contraception is advised to all the sexually active female patients. The routinely followed recommendation for contraception is for 1 month prior to initiation of isotretinoin therapy, during the treatment period, and 1 month after discontinuation of the treatment. However, the recommendation regarding contraception period post isotretinoin therapy is a topic of debate. This issue is further discussed in detail.
| Methods|| |
PubMed research was executed to gather the relevant data needed using the keywords - isotretinoin, pregnancy, contraception, pharmacokinetics, and guidelines. Suitable information regarding isotretinoin was taken from all the publications and guidelines available as well as from the dermatological textbooks. A total of 23 publications could be found on PubMed on the subject and were analysed.
Analysis of data
In the US, isotretinoin-based drugs are sold through a special restricted distribution programme approved by the US Food and Drug Administration (FDA). In 2005 the FDA introduced 'iPLEDGE', a risk management distributed program. The program was initiated to prevent pregnant women from being prescribed or exposed to the medication. It mandated that both male and female users of oral isotretinoin would have to enrol into the National Registry. If this is not achieved, patients will no longer be able to receive the drug. Women of childbearing age have to provide two negative pregnancy tests before their initial prescription, show evidence of another negative pregnancy test before each monthly repeat prescription. Unless continuously abstinent, patient has to comply with the iPLEDGE necessity to use two forms of contraception 1 month before, during, and for 1 month after completion of treatment.,
The European Directive concerned with the prescribing of oral isotretinoin and the European FDA have also implemented a pregnancy prevention programme for females on isotretinoin. According to this programme, female patients are advised to use at least one but ideally TWO methods of contraception for 1 month before starting treatment, including a barrier method, and to continue to use effective contraception throughout the treatment period and for at least 1 month after cessation of treatment. Mandatory pregnancy testing is performed pre-therapy, during and 5 weeks post-therapy.
Kanelleas et al. suggest that patients should agree to at least one and preferably two complementary methods of contraception, including a barrier method, before the initiation of therapy, during treatment and for 5 weeks after the conclusion of it.
Boucher and Beaulac-Baillargeon conclude that patients should be advised to begin using two effective contraceptive methods 1 month before starting isotretinoin and continue using the same during the treatment and 1 month after the last dose.
According to Abroms et al., pregnancy prevention is needed for 1month interval after the isotretinoin therapy ends as 32% of isotretinoin exposed pregnancies occurred during this post-therapy period.,
Thus most recommendations are for 1 month period after stopping the drug. However, there is one paper by Choi et al., which suggested for contraception longer than one month, taking into account the variability in the pharmacokinetics of isotretinoin. It recommends a 3-month window for the use of contraception post isotretinoin therapy to provide an adequate safety margin to prevent fetal exposure, based on more than five elimination half-lives of the drug. There was also a report of suspected isotretinoin-induced ear malformations in a newborn whose mother had taken isotretinoin for 2 years until one month prior to the time when she became pregnant.
As stated by several pharmacokinetics studies of isotretinoin and its metabolites, the harmonic mean elimination half-life of isotretinoin and 4-oxo-isotretinoin following the oral administration of isotretinoin range from 10 to 20 hours and 24 to 29 hours, respectively.,, There is thus evidence of variability in isotretinoin elimination half-life (from 5.3 hours to 7 days) and such variability in the pharmacokinetics may also lead to exposure during pregnancy. Hence, 1 month may not be sufficient for clearing of the drug in all women. According to a study by Nulman et al., the t1/2 of isotretinoin and its metabolite 4-oxo-isotretinoin is generally short, but they observed a prolonged t1/2 in two female patients. This may have happened because of hepatic recirculation. Therefore, in the worst case scenario with t1/2 of approximately 1 week, 5 half-lives will be needed to allow levels to return to baseline.
In the United Kingdom, the Pharmacovigilance Risk Assessment Committee of European medicines agency has adopted recommendations for isotretinoin based on the pharmacovigilance data. It suggests the requirement for two forms of contraception during the treatment and 1 month following the end of treatment, which is determined based on the metabolism of the product.
Another paper on pharmacokinetics of oral isotretinoin by Wiegandand Chou stated that the metabolite of isotretinoin with the longest elimination half-life (oxoisotretinoin), returns nonteratogenic plasma (endogenous) retinoid concentrations within 2 weeks after the end of isotretinoin treatment. Also, retinoic acid, which is thought to be partly responsible for the teratogenic effect ofisotretinoin, takes only 2 days to return to physiologic levels. Hence, the post-therapy contraceptive period of 1 month has been experimentally verified as an adequate safety margin for isotretinoin.
Dai et al. have done an analysis of 88 case reports from pregnant patients in whom conception occurred after discontinuing isotretinoin treatment. Among these, 90% pregnancies occurred within 2 months and 64% occurred within 1 month of discontinuing isotretinoin. Moreover, three women obtained their last dose of isotretinoin within 2 days before the estimated date of conception and eventually delivered normal full-term infants. In these 88 case reports, it was found that there was no increased risk of congenital malformations or spontaneous abortions among these women who completed or discontinued isotretinoin therapy before conception. Also, the incidence rates of congenital malformations and spontaneous or missed abortions in these patients did not show variation from the incidence rates reported in normal females of reproductive age group who had not been exposed to isotretinoin.
| Discussion|| |
As it can be seen from the above analysis, that isotretinoin should be prescribed with caution to women of child bearing age and patients should be provided with detailed information regarding the teratogenic effects of isotretinoin on fetus and contraception while prescribing the drug. Prescribers should counsel sexually active women to select and use two forms of effective contraception simultaneously for at least 1 month prior to initiation of isotretinoin therapy, during therapy, and for 1 month following discontinuation of therapy. Effective contraception should consist of concurrently using both a primary (tubal ligation, partner's vasectomy, intrauterine device, estrogen-containing birth control pills, or topical, injectable, implantable, or insertable hormonal birth control products) and a secondary method of birth control (diaphragm, latex condom, or cervical cap, each to be used with spermicide).
Recently the Central Drugs Standard Control Organisation (CDSCO) from India has issued safety guidelines and labelling rules for isotretinoin, citing the harmful side effects and adverse reactions. These guidelines advocate to avoid pregnancy in patients for 6 months after stopping the treatment.
However, all the recommendations quoted above and the standard dermatological text book suggest only 1month's period of contraception post isotretinoin therapy,,, with European guidelines recommending a 35 day period. No textbook, guideline or publication has mentioned contraception for more than 3 months after conclusion of treatment. In view of the above-stated studies, we feel the Indian recommendation is not justified.
| Conclusion|| |
Considering the variability of isotretinoin pharmacokinetics and taking into account a maximum t1/2 of approximately 1 week, elimination period (five times of t1/2) would be a maximum period of 35 days. This means that the time needed to allow levels to return to baseline would be a 35-day period before safe conception., We therefore feel a 35 day recommendation as stated in recommendation by European directive and Kamellan would be suitable.,
Thus based on pharmacokinetic studies of isotretinoin, recommendation for a wash out period of 35 days post isotretinoin therapy would be adequate and appropriate.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Layton A. The use of isotretinoin in acne. Dermatoendocrinol 2009;1:162-9.
Fogh K, Voorhees JJ, Astrom A. Expression, purification and binding properties of human cellular retinoic acid-binding protein type I and II. Arch Biochem Biophys 1993;300:751-5.
Allenby G, Bocquel MT, Saunders M, Kazmer S, Speck J, Rosenberger M, et al
. Retinoic acid receptors and retinoid X receptors: Interactions with endogenous retinoicacids. Proc Natl Acad Sci USA 1993;90:30-4.
Levin AA, Bosakowski T, Kazmer S, Grippo JF. 13-cis retinoic acid does not bind toretinoic acid receptors alpha, beta and gamma. Toxicologist 1992;12:181.
Ott F, Bollag W, Geiger JM. Oral 9-cis-retinoic acid in acne therapy. Dermatology 1996;193:124-6.
Geiger JM, Hommel L, Harms M, Saurat JH. Oral 13-cis-retinoic acid is superior to9-cis-retinoic acid in sebo suppression in human beings. J Am Acad Dermatol 1996;34:513-5.
Tsukada M, Schröder M, Roos TC, Chandraratna RA, Reichert U, Merk HF, et al
. 13-cis-retinoic acid exerts its specific activity on human sebocytes through selectiveintracellular isomerization to all-trans-retinoic acid and binding to retinoid acid receptors. J Invest Dermatol 2000;115:321-7.
Nelson AM, Gilliland KL, Cong Z, Thiboutot DM. 13-cis-retinoic acid inducesapoptosis and cell cycle arrest in human SEB-1 sebocytes. J Invest Dermato 2006;126:2178-89.
Stern RS. When a uniquely effective drug is teratogenic: The case of isotretinoin. NEngl J Med 1989;320:1007-9.
Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Gilstrap LC, Wenstrom KD, editors. Williams Obstetrics. 22nd
ed. New York:McGraw-Hill; 2005.
Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N
Engl J Med 1998;338:1128-37.
Layton AM, Dreno B, Gollnick HP, Zouboulis CC. A review of the European Directive for prescribing systemic isotretinoin for acne vulgaris. J Eur Acad Dermatol Venereol 2006;20:773-6.
Kanelleas AI, Thornton S, Berth-Jones J. Suggestions for effective contraception in isotretinoin therapy. Br J Clin Pharmacol 2009;67:137-8.
Boucher N, Beaulac-Baillargeon L. Pregnancy prevention among women taking isotretinoin: Failure to comply with the recommendations. Can Fam Physician 2006;52:338-9.
Abroms L, Maibach E, Lyon-Daniel K, Feldman SR. What is the best approach to reducing birth defects associated with isotretinoin? PLoS Med 2006;3:e483.
Choi JS, Koren G, Nulman I. Pregnancy and isotretinoin therapy.CMAJ 2013;185:411-3.
Wiegand UW, Chou RC. Pharmacokinetics of oral isotretinoin. J Am Acad Dermatol 1998;39:S8-12.
Lee SM, Kim HM, Lee JS, Yoon CS, Park MS, Park KI, et al
. A case of suspected isotretinoin-induced malformation in a baby of a mother who became pregnant one month after discontinuation of the drug. Yonsei Med J 2009;50:445-7.
Brazzell RK, Vane FM, Ehmann CW, Colburn WA. Pharmacokinetics of isotretinoin during repetitive dosing to patients. Eur J Clin Pharmacol 1983;24:695-702.
Brazzell RK, Colburn WA. Pharmacokinetics of the retinoids isotretinoin and etretinate. A comparative review. J Am Acad Dermatol 1982;6:643-51.
Khoo KC, Reik D, Colburn WA. Pharmacokinetics of isotretinoin following a single oral dose. J Clin Pharmacol 1982;22:395-402.
Nulman I, Berkovitch M, Klein J, Pastuszak A, Lester RS, Shear N, et al
. Steady-state pharmacokinetics of isotretinoin and its 4-oxo metabolite: Implications for fetal safety. J Clin Pharmacol 1998;38:926-30.
Pharmacovigilance Risk Assessment Committee. Retinoids containing medicinal products (EMA/254364/2018). Canary Wharf, London: European Medicines Agency; 2018.
Dai WS, Hsu M, Itri LM. Safety of pregnancy after discontinuation of isotretinoin. Arch. Dermatol 1989;125:362-5.
Brinker A, Kornegay C, Nourjah P. Trends in adherence to a revised risk-management program designed to decrease or eliminate isotretinoin-exposed pregnancies: Evaluation of the Accutane SMART program. Arch Dermatol 2005;141:563-9.
Vahlquist A, Saurat JH. Retinoids. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, editors. FitzPatrick's Dermatology in General Medicine. 8th
ed. USA: Mac Graw Hill; 2012.p. 2759-66.
Breathnach SM, Smith CH, Chalmers RJ, Hay RJ. Systemic Therapy. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook's Text Book of Dermatology. 8th
ed. Oxford: Blackwell Publishers; 2010.p. 74.1-53.
Timothy J. Patton, Laura K. Ferris. Systemic retinoids. In: Wolverton SE, editors. Comprehensive Dermatologic Drug Therapy. 3rd
ed. Edinburgh: Saunders/Elsevier; 2013.p. 252-68.